{"id":716,"date":"2004-09-01T12:01:00","date_gmt":"2004-09-01T10:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/valsartan-und-amlodipin-in-der-prophylaxe-kardiovaskulaerer-hochdruckschaeden-im-wesentlichen-wirkungsgleich-die-value-studie"},"modified":"2004-09-01T12:01:00","modified_gmt":"2004-09-01T10:01:00","slug":"valsartan-und-amlodipin-in-der-prophylaxe-kardiovaskulaerer-hochdruckschaeden-im-wesentlichen-wirkungsgleich-die-value-studie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/valsartan-und-amlodipin-in-der-prophylaxe-kardiovaskulaerer-hochdruckschaeden-im-wesentlichen-wirkungsgleich-die-value-studie","title":{"rendered":"Valsartan und Amlodipin in der Prophylaxe kardiovaskul\u00e4rer Hochdrucksch\u00e4den im Wesentlichen wirkungsgleich. Die VALUE-Studie"},"content":{"rendered":"<p>Im Juli erschien die VALUE-Studie (1) im Lancet. 15245 Hypertoniker mit hohem kardiovaskul\u00e4rem Risiko wurden in diese doppeltblinde randomisierte Studie eingeschlossen. Das mittlere Lebensalter der Patienten war 67 Jahre, der Blutdruck 155\/87 mm Hg und 32% hatten Diabetes. Erster m\u00f6glicher Kombinationspartner von Valsartan (Diovan\u00ae, Provas\u00ae) bzw. Amlodipin (Norvasc\u00ae) bei unzureichender antihypertensiver Wirkung war Hydrochlorothiazid. Als [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Im Juli erschien die VALUE-Studie (1) im Lancet. 15245 Hypertoniker mit hohem kardiovaskul\u00e4rem Risiko wurden in diese doppeltblinde randomisierte Studie eingeschlossen. Das mittlere Lebensalter der Patienten war 67 Jahre, der Blutdruck 155\/87 mm Hg und 32% hatten Diabetes. Erster m\u00f6glicher Kombinationspartner von Valsartan (Diovan\u00ae, Provas\u00ae) bzw. Amlodipin (Norvasc\u00ae) bei unzureichender antihypertensiver Wirkung war Hydrochlorothiazid. Als [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1611,316,309,312,314,313,315,317,320,311,307,319,310,324,325,306,366,1834],"class_list":["post-716","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-amlodipin","tag-angiotensin-ii-antagonisten","tag-angiotensin-ii-blocker","tag-angiotensin-ii-inhibitoren","tag-angiotensin-ii-rezeptor-antagonisten","tag-angiotensin-ii-rezeptor-blocker","tag-angiotensin-ii-rezeptor-inhibitoren","tag-at-ii-antagonisten","tag-at-ii-blocker","tag-at-ii-inhibitoren","tag-at-ii-rezeptor-antagonisten","tag-at-ii-rezeptor-blocker","tag-at-ii-rezeptor-inhibitoren","tag-blutdruck","tag-hypertonie","tag-sartane","tag-valsartan","tag-value-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=716"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/716\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=716"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=716"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}